BRPI0615046C1 - uso de um composto - Google Patents

uso de um composto

Info

Publication number
BRPI0615046C1
BRPI0615046C1 BRPI0615046A BRPI0615046A BRPI0615046C1 BR PI0615046 C1 BRPI0615046 C1 BR PI0615046C1 BR PI0615046 A BRPI0615046 A BR PI0615046A BR PI0615046 A BRPI0615046 A BR PI0615046A BR PI0615046 C1 BRPI0615046 C1 BR PI0615046C1
Authority
BR
Brazil
Prior art keywords
disorder
compounds
pharmaceutically acceptable
acceptable salts
disease
Prior art date
Application number
BRPI0615046A
Other languages
English (en)
Portuguese (pt)
Inventor
Reaume Andrew
S Saporito Michael
Original Assignee
Melior Discovery Inc
Melior Pharmaceuticals I Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Discovery Inc, Melior Pharmaceuticals I Inc filed Critical Melior Discovery Inc
Publication of BRPI0615046A2 publication Critical patent/BRPI0615046A2/pt
Publication of BRPI0615046B1 publication Critical patent/BRPI0615046B1/pt
Publication of BRPI0615046B8 publication Critical patent/BRPI0615046B8/pt
Publication of BRPI0615046C1 publication Critical patent/BRPI0615046C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
BRPI0615046A 2005-08-22 2006-08-22 uso de um composto BRPI0615046C1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70979805P 2005-08-22 2005-08-22
US60/709798 2005-08-22
US80853306P 2006-05-26 2006-05-26
US60/808533 2006-05-26
PCT/US2006/032788 WO2007024863A2 (en) 2005-08-22 2006-08-22 Methods and formulations for modulating lyn kinase activity and treating related disorders

Publications (4)

Publication Number Publication Date
BRPI0615046A2 BRPI0615046A2 (pt) 2011-04-26
BRPI0615046B1 BRPI0615046B1 (pt) 2020-01-14
BRPI0615046B8 BRPI0615046B8 (pt) 2020-01-28
BRPI0615046C1 true BRPI0615046C1 (pt) 2021-05-25

Family

ID=37635750

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615046A BRPI0615046C1 (pt) 2005-08-22 2006-08-22 uso de um composto

Country Status (11)

Country Link
US (8) US7776870B2 (enExample)
EP (1) EP1924262B1 (enExample)
JP (1) JP5113752B2 (enExample)
KR (2) KR101452518B1 (enExample)
AT (1) ATE533488T1 (enExample)
AU (1) AU2006283211B2 (enExample)
BR (1) BRPI0615046C1 (enExample)
CA (1) CA2620065C (enExample)
IL (1) IL189603A0 (enExample)
NZ (1) NZ565955A (enExample)
WO (1) WO2007024863A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
EP2120581A4 (en) * 2007-02-20 2011-03-16 Melior Pharmaceuticals I Inc METHODS OF IDENTIFYING LYN KINASE ACTIVATORS
US20100160339A1 (en) * 2007-05-21 2010-06-24 Mayo Foundation For Medical Education And Research Treating pancreatitis
EP2180894A4 (en) * 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc METHOD OF ACTIVATING IRS-1 AND ACT
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
WO2011150300A1 (en) * 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
SG11201403207WA (en) * 2011-12-12 2014-09-26 Melior Pharmaceuticals I Inc Treatment of type i and type ii diabetes
WO2014100636A2 (en) * 2012-12-20 2014-06-26 The Trustees Of Columbia University In The City Of New York Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator
JO3546B1 (ar) 2015-01-09 2020-07-05 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
CA3088178A1 (en) 2018-02-21 2019-08-29 Melior Pharmaceuticals I, Inc. Treatment of liver diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
BE790125A (fr) * 1971-10-29 1973-04-16 Pfizer Nouvelles pyrimidinones et nouvelles hydroxypyrimidines
US3922345A (en) * 1971-10-29 1975-11-25 Pfizer Pyrimidinones and hydroxy pyrimidines
US4080454A (en) 1976-07-16 1978-03-21 Pfizer Inc. 5-M-Tolyloxyuracil, anti-ulcer agent
US4612376A (en) 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB9214720D0 (en) 1992-07-10 1992-08-19 Wellcome Found Enzyme inhibitors
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5476855A (en) 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US6900304B2 (en) 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US20020019346A1 (en) 1997-05-21 2002-02-14 Children's Medical Center Corporation Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6410255B1 (en) 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0104422D0 (en) 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
US20050208054A1 (en) 2003-12-09 2005-09-22 University Of Massachusetts Methods of identifying insulin response modulators and uses therefor
EP1541694A1 (en) 2003-12-12 2005-06-15 Sirenade Pharmaceuticals AG Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase
US20060035302A1 (en) 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
WO2007016975A1 (en) 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Kinase and phosphatase assays based on fret
US20070025953A1 (en) 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
SI1924264T1 (sl) 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
KR100881728B1 (ko) 2007-05-04 2009-02-06 주식회사 하이닉스반도체 루테늄전극을 구비한 반도체소자 및 그 제조 방법
EP2180894A4 (en) 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc METHOD OF ACTIVATING IRS-1 AND ACT
US8552184B2 (en) 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US9278134B2 (en) 2008-12-29 2016-03-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP3110946B1 (en) 2014-02-24 2021-09-01 Energesis Pharmaceuticals Inc. Methods and compositions for inducing differentiation of human brown adipocyte progenitors
EP3609500B1 (en) * 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes

Also Published As

Publication number Publication date
CA2620065C (en) 2011-03-29
US11033548B2 (en) 2021-06-15
AU2006283211A1 (en) 2007-03-01
JP2009506043A (ja) 2009-02-12
KR20080059164A (ko) 2008-06-26
KR20140096141A (ko) 2014-08-04
US7776870B2 (en) 2010-08-17
US20160136165A1 (en) 2016-05-19
WO2007024863A2 (en) 2007-03-01
ATE533488T1 (de) 2011-12-15
KR101577554B1 (ko) 2015-12-14
JP5113752B2 (ja) 2013-01-09
US20070093516A1 (en) 2007-04-26
US20190321362A1 (en) 2019-10-24
US20180125845A1 (en) 2018-05-10
US9763945B2 (en) 2017-09-19
CA2620065A1 (en) 2007-03-01
US8343985B2 (en) 2013-01-01
US20140163054A1 (en) 2014-06-12
KR101452518B1 (ko) 2014-10-21
BRPI0615046B1 (pt) 2020-01-14
US9216959B2 (en) 2015-12-22
NZ565955A (en) 2011-08-26
US20100278804A1 (en) 2010-11-04
US12070461B2 (en) 2024-08-27
US20210361652A1 (en) 2021-11-25
IL189603A0 (en) 2008-08-07
US10251883B2 (en) 2019-04-09
EP1924262B1 (en) 2011-11-16
AU2006283211B2 (en) 2012-06-21
HK1120738A1 (en) 2009-04-09
BRPI0615046A2 (pt) 2011-04-26
US8835448B2 (en) 2014-09-16
US20130095182A1 (en) 2013-04-18
BRPI0615046B8 (pt) 2020-01-28
WO2007024863A3 (en) 2007-08-02
EP1924262A2 (en) 2008-05-28
WO2007024863A9 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20084256L (no) DPP IV inhibitorformuleringer
CL2009001936A1 (es) Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006).
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
IL189603A0 (en) Methods and formulations for modulating lyn kinase activity and treating related disorders
MX2009008100A (es) Preparacion solida que comprende alogliptina y pioglitazona.
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
NO20075111L (no) Farmasoytisk sammensetning
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
CO6300953A2 (es) Antagonistas del receptor mineralcorticoide y metodos de uso
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
EA201170512A1 (ru) Композиция для перорального введения
EA201000926A1 (ru) Пиперазины в качестве агентов против ожирения
BRPI0714811A2 (pt) Modulador de receptor de corticóide, seus sais, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos e sais na fabricação de medicamento
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
EA200970022A1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MELIOR PHARMACEUTICALS I, INC. (US)

Free format text: TRANSFERIDO DE: MELIOR DISCOVERY, INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2558 DE 14/01/2020 QUANTO AO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067220, DE 23/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI